For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for MKS Instruments Inc. (MKSI) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -36 (−100…+100 Quality+Value blend) · Quality -16 · Value -53 · Sentiment 59 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
MKS Instruments Inc.
MKSI NASDAQMKS Instruments Inc. is a technology company that provides foundational solutions for advanced manufacturing and high-performance electronics. The company supplies instruments, subsystems, systems, process control technologies, and specialty chemical products used in semiconductor chip fabrication, printed circuit board production, advanced packaging, and a wide range of specialty industrial applications. Its portfolio spans pressure and flow measurement and control, gas and vapor delivery, gas composition analysis, vacuum technology, power and reactive gas products, lasers, photonics, optics, precision motion control, vibration control, and laser-based manufacturing systems. These offerings help customers measure, monitor, deliver, analyze, power, and control critical process parameters to improve performance, yield, and productivity in complex manufacturing environments. MKS Instruments Inc. serves markets including semiconductor manufacturing, industrial technologies, life and health sciences, research, and defense. The company is headquartered in Andover, Massachusetts, and operates globally through multiple business divisions and product groups that support leading technology and industrial companies.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 4.37
Total Equity: $2.72B
Shares: 67,700,000
Total Debt: $4.20B
Cash: $418.00M
EBITDA: $872.00M
Total Debt: $4.20B
Cash: $418.00M
Revenue: $3.93B
Revenue: $3.93B
Revenue: $3.93B
Total Equity: $2.72B
Tax Rate: 3.0%
Equity: $2.72B
Total Debt: $4.20B
Cash: $418.00M
Current Liabilities: $927.00M
Long-Term Debt: $4.15B
Total Debt: $4.20B
Total Equity: $2.72B
Shares: 67,700,000
Shares: 67,700,000
CapEx: -$148.00M
Shares: 67,700,000
Stock Price: $310.73
Net Income: $295.00M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 15, 2026 1:09pm (8d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.9B | $3.5B | $3.6B | $3.6B | $3.9B |
| Cost of Revenue | $1.6B | $2.0B | $2.0B | $1.9B | $2.1B |
| Gross Profit | $1.4B | $1.5B | $1.6B | $1.7B | $1.8B |
| Operating Expenses | $681.3M | $930.0M | $3.2B | $1.2B | $1.3B |
| Operating Income | $698.9M | $617.0M | -$1.6B | $498.0M | $528.0M |
| Net Income | $551.4M | $333.0M | -$1.8B | $190.0M | $295.0M |
| EBITDA | $803.0M | $833.0M | -$1.2B | $846.0M | $872.0M |
| EPS | $9.95 | $5.57 | $-27.54 | $2.82 | $4.39 |
| EPS (Diluted) | $9.90 | $5.56 | $-27.54 | $2.81 | $4.37 |
Balance Sheet (Annual)
Last updated: Aug 15, 2026 1:00pm (8d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | — | — | $507.0M | $420.0M | $418.0M |
| Total Current Assets | $2.1B | $2.8B | $2.7B | $2.5B | $2.5B |
| Total Assets | $4.5B | $11.5B | $9.1B | $8.6B | $8.8B |
| Current Liabilities | $460.8M | $952.0M | $848.0M | $775.0M | $927.0M |
| Long-Term Debt | $807.9M | $4.8B | $4.7B | $4.5B | $4.2B |
| Total Liabilities | $1.7B | $7.0B | $6.6B | $6.3B | $6.1B |
| Total Equity | $2.9B | $4.5B | $2.5B | $2.3B | $2.7B |
| Retained Earnings | $2.0B | $2.3B | $373.0M | $503.0M | $711.0M |
Cash Flow (Annual)
Last updated: Aug 15, 2026 1:09pm (8d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $639.5M | $529.0M | $319.0M | $528.0M | $645.0M |
| Capital Expenditure | -$86.7M | -$164.0M | -$87.0M | -$118.0M | -$148.0M |
| Free Cash Flow | $552.8M | $365.0M | $232.0M | $410.0M | $497.0M |
| Acquisitions (net) | -$268.4M | -$4.5B | $0 | $0 | — |
| Net Debt Issued / (Repaid) | -$15.2M | -$962.0M | -$403.0M | -$2.4B | -$451.0M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | $0 | $0 | -$45.0M |
| Net Change in Cash | $358.0M | -$57.0M | -$34.0M | -$161.0M | -$39.0M |
Growth Trends (YoY %)
Last updated: Aug 15, 2026 1:09pm (8d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +20.3% | +2.1% | -1.0% | +9.6% |
| Gross Profit Growth | +12.1% | +6.1% | +4.0% | +7.6% |
| Operating Income Growth | -11.7% | -351.9% | +132.0% | +6.0% |
| Net Income Growth | -39.6% | -652.9% | +110.3% | +55.3% |
| EBITDA Growth | +3.7% | -238.9% | +173.1% | +3.1% |
Dividend History (Last 20)
Last updated: Aug 15, 2026 1:00pm (8d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-08-25 | $0.25 | — | — | — |
| 2026-06-03 | $0.25 | — | — | — |
| 2026-02-23 | $0.25 | — | — | — |
| 2025-11-24 | $0.22 | — | — | — |
| 2025-08-25 | $0.22 | — | — | — |
| 2025-05-27 | $0.22 | — | — | — |
| 2025-02-24 | $0.22 | — | — | — |
| 2024-11-25 | $0.22 | — | — | — |
| 2024-08-26 | $0.22 | — | — | — |
| 2024-05-24 | $0.22 | — | — | — |
| 2024-02-23 | $0.22 | — | — | — |
| 2023-11-24 | $0.22 | — | — | — |
| 2023-08-25 | $0.22 | — | — | — |
| 2023-05-26 | $0.22 | — | — | — |
| 2023-02-24 | $0.22 | — | — | — |
| 2022-11-25 | $0.22 | — | — | — |
| 2022-08-05 | $0.22 | — | — | — |
| 2022-05-26 | $0.22 | — | — | — |
| 2022-02-25 | $0.22 | — | — | — |
| 2021-11-26 | $0.22 | — | — | — |
Deep Analysis
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-15AI compute buildout raises both wafer starts at leading edge and, more importantly, the process intensity per wafer — more deposition/etch steps, more advanced packaging, higher-layer-count AI server PCBs — which lifts MKS content per tool and pulls through recurring Atotech chemistry and laser via-drilling consumables.
AI-aided design and simulation compress the engineering-hours barrier that protects MKS's more commoditized boxes (power supplies, basic flow control, standard optics), arming Chinese localization programs and giving OEMs like AMAT/LAM a cheaper path to in-sourcing subsystems — visible already in the -3.8% share gap versus industry growth.
Whether content-per-tool and advanced-packaging/PCB chemistry revenue grow faster than the industry while mid-tier subsystem share erodes. Watch segment disclosure: Materials Solutions (Atotech) and Photonics growth versus Vacuum & Analysis, and any OEM design-out announcement.
Qualified position inside OEM tool bills-of-material and fab process recipes — requalification risk means incumbency compounds; plus Atotech's plating chemistry formulations and application know-how, which are wet-chemistry empirical IP, not code.
AI Lens thesis
MKS sells physical, process-critical hardware and consumable chemistry into semiconductor and PCB manufacturing; none of the monetized unit is information-processing, so AI cannot disintermediate the transaction or eliminate the interface. AI instead operates on three channels: (1) demand — AI accelerators, HBM, CoWoS-class packaging and high-layer AI server boards are the most process-intensive products ever built, raising MKS dollar content per wafer and per board; (2) MKS's own cost base — AI can compress application-engineering, field-service diagnostics and design cycles against a 47% gross margin, though much of that is competed away to OEM customers who dictate pricing; (3) competitor arming — cheap design intelligence narrows the engineering gap in standardized components where Chinese entrants and OEM in-sourcing are already targeting. Net: a physical-scarcity beneficiary whose upside is levered to AI capex durability and whose real vulnerability is share, cyclicality and the Atotech-era balance sheet, not AI substitution.
What the market may be underestimating
Upside Atotech's chemistry is a consumable, per-panel revenue stream tied to AI server board complexity — if mSAP/high-layer-count adoption scales with AI infrastructure, MKS gains a recurring, less cyclical revenue line the market still models as capital-equipment cyclicality.
Downside MKS's installed-base telemetry could become the basis for fab-level predictive process control, but the fabs — not MKS — own that data and are the natural aggregators; if OEMs and fabs build the AI process-control layer, MKS is pushed toward being a commodity actuator supplier with shrinking software-value capture.
Outcome range spread 45 · unresolved
Growth Outlook
Analyzed 2026-08-17 16:12The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The raw quarterly trajectory tells a clear cyclical-recovery story: revenue has climbed from $896M in Q3 2024 to $1.25B in Q2 2026 — that's 40% growth in seven quarters — while net income margin rebuilt from ~7% to 14%. Q2 2026's $175M NI annualizes to roughly $700M, putting forward P/E closer to 30x than the trailing 71x the synthesis fixates on. FCF of $497M against a $21B market cap is a ~2.4% yield, and the FCF CAGR of 46% reflects operational leverage flowing through as WFE demand rebuilds. This is not the picture of a business that deserves a $41 fair value stamp.
The synthesis verdict of $41.48 fair value — an 87% haircut — is almost certainly wrong in magnitude, even if directionally skeptical. A DCF that outputs "worth 13% of current price" on a company generating $700M annualized earnings and $500M FCF with accelerating topline is either using trough-cycle inputs projected forever or discounting the semi-cap recovery entirely. The market forces model calling MKSI a "leveraged mid-cycle value trap" is more defensible: $4.2B debt against $2.7B equity and $418M cash is genuinely levered, and interest burden explains why net margins stay in the 7-14% band despite 47% gross margins. But "value trap" implies the cycle doesn't extend, and the Q2 acceleration argues the opposite — HBM, advanced packaging, and CHIPS-era fab buildouts are running hot, and MKS's vacuum/photonics/materials portfolio genuinely does attach to that capex.
The contrarian case worth taking seriously isn't the DCF's $41 — it's that we're near the top of a semi-cap cycle that the market always mis-times. ASML, LRCX, AMAT are all trading at cycle-peak multiples; if 2026-2027 marks the WFE peak, MKSI's earnings could compress 30-40% and the 30x forward becomes 50x on trough earnings. Insider activity supports this read: ten straight sales across May-June 2026, zero buys, right as revenue prints its best quarter in years. That's textbook insiders monetizing into cyclical strength. The narrative layer's "platform-monopoly" framing overstates MKSI's moat — they're a critical supplier, not an ASML-style monopoly, and Chinese domestic substitution is a real 3-5 year threat on the vacuum/gas-delivery side. ROIC of 7.9% is not "elite compounder" territory; it's decent industrial returns that don't justify 6.3x EV/revenue.
My verdict: the synthesis is right that MKSI is overvalued at $310, wrong that it's worth $41. Fair value at mid-cycle earnings power of ~$700-750M NI, at a defensible 22-25x for a levered cyclical with real but not monopoly moats, lands around $180-200. That's a 35-40% downside, not 87%. I dissent from the synthesis on magnitude but agree on direction. The setup — accelerating fundamentals, insider selling, cycle-peak semi-cap comps, thin FCF yield, leveraged balance sheet — is a classic "sell into strength" rather than a short-the-fraud thesis. Anyone long here is betting the WFE cycle extends through 2028 and margins hold at 14%+ through the next downturn; history says that bet loses.
GPT Reading
At $310.73, the market is capitalizing MKS at $21.0 billion against a business that generated $3.93 billion of 2025 revenue, $528 million of operating income, $295 million of net income, and $497 million of free cash flow. Even giving credit for the obvious improvement in the 2026 run-rate, the valuation is stretched. The last four quarters produced about $4.35 billion of revenue and $440 million of net income, so the stock is still around 48x trailing earnings and roughly 4.8x trailing sales for a cyclical instrumentation and semiconductor-exposed supplier carrying $4.20 billion of debt and only $418 million of cash. What stands out in the raw numbers is not a business compounding at software-like rates, but one recovering from a trough: quarterly revenue moved from $896 million in 2024 Q3 to $1.25 billion by 2026 Q2, while net margin climbed from 6.9% to 14.0%. That is real improvement, but it looks like classic cyclical operating leverage rather than proof of a permanently re-rated earnings base.
The balance between quality and leverage matters here. Gross margin is healthy at 46.7%, the current ratio of 2.7x is fine, and 2025 operating cash flow of $645 million versus net income of $295 million says the earnings are backed by cash. But this is also a company with debt equal to 1.55x equity and a net debt load near $3.8 billion. On 2025 operating income of $528 million, that leverage is material; the business can service it in an upcycle, but it reduces the room for error if semiconductor capital spending softens. The annual history reinforces that caution: revenue has been basically range-bound between $3.55 billion and $3.93 billion from 2022 through 2025, while profitability has been volatile enough to include a 2023 net loss of $1.84 billion. Some of that was clearly impairment-related, but it is still evidence that this is not a smooth secular compounder deserving an unquestioned premium multiple.
The quarterly progression does show why bulls are excited. Revenue rose sequentially from $936 million in 2025 Q1 to $973 million, $988 million, $1.03 billion, $1.08 billion, and then $1.25 billion, while net income went from $52 million to $175 million over that span. If I annualize the latest quarter, you get a rough earnings power of $700 million, which would imply a forward P/E around 30x. That is a lot less absurd than the 71x headline annual multiple, and it suggests the market is looking through the depressed 2025 earnings base. The problem is that 30x is still a rich price for a company whose medium-term revenue CAGR is only 4.2%, whose ROIC is 7.9%, and whose end markets are capex-driven. To make $310 work comfortably, you need to believe the June 2026 quarter is not a peak-ish recovery quarter but the start of a sustained step-up in both revenue and margins. The data so far are supportive of recovery, not of that stronger claim.
The best argument against my bearish read is that the annual metrics badly understate current earning power. Net income of $440 million over the last four quarters is already 49% above 2025’s $295 million, and because the most recent quarter delivered a 14% net margin on $1.25 billion of sales, there is a plausible path to $5.0 billion-plus revenue and perhaps $700-$800 million of annualized net income if wafer fab equipment, advanced packaging, and service/consumables demand all stay firm. On that view, leverage becomes an equity amplifier, not a threat, and the stock at $310 is trading closer to the high-20s on normalized earnings, which is not crazy for a strategic supplier with improving mix and strong cash conversion. I weigh that case less heavily because the historical record here is too cyclical to pay a secular-growth multiple before seeing a full year of double-digit margins, and because the insider tape is one-way selling recently, which does not prove overvaluation but also does not support the “still early” bull narrative.
What would change my mind is straightforward: if MKS can put up two to three more quarters around or above $1.2 billion of revenue while holding net margins at 12%-14%, and convert that into a clear annualized earnings run-rate above $750 million with debt moving down meaningfully from $4.20 billion, then the current valuation starts to look more like a justified anticipation of normalized earnings than a speculative overshoot. Conversely, if revenue stalls back near $1.0-$1.1 billion or margins slip back into the high-single digits, the stock should de-rate sharply because the present price leaves very little room for a normal cyclical wobble. My base case is that this is a good company in a good part of tech manufacturing, but at $310 the market is paying for the recovery as if it were already durable and largely de-risked.
Grok Reading
The quarterly tape is unambiguous about the near-term operating recovery. Revenue has climbed from $936M in Q1 2025 to $1.25B in the June 2026 quarter, a clean sequential acceleration that lifts the trailing annualized run-rate well above the $3.93B full-year 2025 print. Net margin expanded from 5.6% to 14% over that same stretch, and the latest quarter alone delivered $175M of net income—more than half of all of 2025’s $295M. Free cash flow of $497M against only $148M of capex confirms the business is capital-light and converting the upswing into cash. The 2023 wipeout (operating loss of $1.55B, net loss of $1.84B) was clearly impairment-driven rather than a permanent franchise break; 2024–2025 restored positive operating income of roughly $500M. So the cycle is real, margins are flexing upward, and cash generation is healthy.
That said, the price of $310.73 and $21B market cap are pricing a structural re-rating that the historical growth rates simply do not support. Revenue CAGR over the available window is only 4.2%; even the recent 9.6% year-on-year step-up is mid-cycle catch-up, not a new secular slope. At 71× trailing earnings, 5.4× sales and 28× EV/EBITDA, the multiple assumes that the $1.25B quarter becomes the permanent base, that net margins hold in the mid-teens, and that ROIC climbs well above the current 7.9% for a decade. Net debt of roughly $3.8B (total debt $4.2B versus cash of only $418M) against equity of $2.72B leaves a debt-to-equity ratio of 1.55 and a thin interest-coverage cushion if the semi-equipment cycle rolls over. Every one of the last ten insider transactions is a sale. The stock is therefore a leveraged bet on peak-cycle permanence rather than a compounder purchased at a reasonable entry.
The strongest counter-argument is that the June quarter already annualizes near $5B of revenue; if advanced-packaging and AI-driven fab spend keep that run-rate intact and push net income toward $600M, the forward multiple compresses into the mid-30s and the FCF yield becomes respectable. Gross margin of 47% and the installed-base service/consumable attach give real operating leverage, and a true multi-year fab-duplication cycle (geopolitical plus technology) could justify higher normalized earnings power than the 4% historical CAGR implies. In that world the $41 DCF anchor looks too static and the narrative premium is partly earned. I weigh this less heavily because even that optimistic earnings power still leaves a cyclical, highly leveraged instrument company trading at a large premium to peers, with no evidence yet that Chinese competition or customer vertical integration will stay at bay, and with every insider selling into the rally.
I would flip to neutral or constructive only if the next two quarters both clear $1.3B revenue with net margins sustained above 13%, accompanied by explicit net-debt reduction of at least $500M and order commentary that locks in a multi-year advanced-packaging backlog rather than a single up-cycle spike.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
MKS is a mature earner in scientific/technical instruments with revenue rebuilding from $2.95B (2021) to $3.93B (2025), gross margins holding in a 44-48% band, and FCF recovering to $497M in 2025 after a bruising 2023 that included a $-1.84B net loss and -42.9% operating margin (impairment/integration-driven, consistent with the Atotech deal digestion). Earnings quality checks are clean: OCF/NI 1.51x, accruals -7.1% of assets, Beneish M -2.58, Altman Z 3.05 (safe). Cash conversion is real, not accrual-flattered.
Verify before trusting this (5)
- Debt maturity schedule and covenant terms tied to the Atotech financing
- Segment-level exposure to semi capex cycle vs. specialty industrial/electronics
- Customer concentration among top semi equipment OEMs
- Whether SBC grant sizing and share creep continue at 5%/yr or moderate
- Nature of the 2023 impairment/loss - goodwill vs. operating
The e2e composite fair value of $44.12 and signal-adjusted $41.48 are almost certainly runaway artifacts - a ~87% implied downside on a real, cash-generative instruments franchise with $21B of market cap fails the sanity check, and the EPV floor of -$11.72 confirms the method is unstable (likely penalizing a cyclical trough in earnings and the levered balance sheet). I discount both heavily. The DCF at $72 is directionally more useful but still points the same way: even that method, which typically extrapolates current trends, lands at less than a quarter of today's price. Backing into what $310 requires: mid-teens ROIC sustained through a full semi-cap cycle, continued margin expansion, and debt paydown without further dilution - a stack of assumptions that leaves no margin of safety. The Company-Quality lens rates this Solid, not Strong, with $3.78B net debt and ~5% annual share creep partially offset by buybacks; that profile deserves a market multiple, not a peak-cycle premium. Net: the deserved value is meaningfully below the price. I can't pin the gap precisely because the model outputs are noisy, but even generously doubling the DCF to $140-160 to account for cycle-normalization leaves the stock 50%+ above a defensible anchor. This is Rich, not catastrophically overvalued - the business is real - but there is no discount here to underwrite.
Verify before trusting this (5)
- Normalized mid-cycle operating margin and ROIC assumptions vs peak-cycle 2024-25 prints
- Debt paydown schedule and refinancing rates on the Atotech acquisition debt
- Semi-cap wafer fab equipment cycle guidance from ASML/AMAT/LRCX read-throughs
- Segment-level growth in Photonics and Vacuum vs Materials to gauge cycle exposure
- SBC as % of revenue and pace of net share reduction going forward
The macro tape is mildly risk-on (VIX 14.3, S&P a whisker off highs) and MKSI's beta near 2 means it inhales that oxygen more than most. More importantly, the active narrative is a platform-monopoly / semi-cap-equipment story fused with the AI capex mania, which is exactly the archetype the market is paying up for right now. The Q2 print, revenue up 28% citing semis and AI, is fresh fuel and lands into a tape already rewarding optical and semi-adjacent names (Coherent's pre-print run-up is a tell for the cohort). Analyst tone and peer action are corroborating rather than fighting the story, and momentum is strong-positive with recent 9.6% pace outrunning the long-term 4.2%. The countervailing pressure is real but secondary: higher rates and a stretched market PE are a background headwind for high-beta names, and the narrative's durability is only 'moderate' with low cult coefficient, so the story can fade if AI-capex chatter cools or a cycle-peak worry gets a headline. Net-net, right now the non-fundamental wind is at this ticker's back, not in its face.
Verify before trusting this (4)
- Whether analyst target revisions post-Q2 print are being raised in line with the 28% growth or staying anchored (divergence would flag fading conviction).
- Any softening in AI-capex commentary from ASML, AMAT, LRCX, KLAC that would puncture the semi-cap narrative cohort.
- VIX breaking above 18-20 or 10y pushing toward 5%, which would hit beta-2 names disproportionately.
- China semi-equipment competition or export-control headlines that could dent the chokepoint story.
MKS sells physical, process-critical hardware and consumable chemistry into semiconductor and PCB manufacturing; none of the monetized unit is information-processing, so AI cannot disintermediate the transaction or eliminate the interface. AI instead operates on three channels: (1) demand — AI accelerators, HBM, CoWoS-class packaging and high-layer AI server boards are the most process-intensive products ever built, raising MKS dollar content per wafer and per board; (2) MKS's own cost base — AI can compress application-engineering, field-service diagnostics and design cycles against a 47% gross margin, though much of that is competed away to OEM customers who dictate pricing; (3) competitor arming — cheap design intelligence narrows the engineering gap in standardized components where Chinese entrants and OEM in-sourcing are already targeting. Net: a physical-scarcity beneficiary whose upside is levered to AI capex durability and whose real vulnerability is share, cyclicality and the Atotech-era balance sheet, not AI substitution.
None surfaced.
Verify before trusting this (8)
- OEM in-sourcing announcements
- China domestic subsystem qualification wins
- Content-per-tool disclosure
- Advanced packaging revenue mix
- Laser via-drilling design wins
- Chemistry consumable growth rate
- Leading-edge wafer start trends
- Advanced packaging capacity additions
The world is spending on compute capacity, and every wafer and every advanced package passes through pressure/flow control, vacuum, reactive gas, lasers and plating chemistry. That places MKS on the right side of the decade's biggest capital cycle, and the chokepoint/qualification dynamic means the position is defended rather than won each quarter. The offsets are structural in a different way: this is capital equipment, so the slope is set by other companies' capex committees, not by MKS's own execution; and geopolitical fragmentation cuts both ways — more fabs in more places, but also state-backed domestic substitution in China for the more commoditized parts of the portfolio. Net: the business direction is up, the amplitude is borrowed from a cycle, and the durable part is the consumables/aftermarket annuity underneath.
Prediction unavailable. valuation-synthesis has no result for MKSI — the prediction needs its fair-value anchors.